← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
151	151 NewcelX Ltd NCEL $14.4M	–	–	–	–
152	152 DELISTED NKGen Biotech, Inc. Common Stock NKGN	–	–	–	–
153	153 Nkarta NKTX $129M	–	–	–	–
154	154 Intellia Therapeutics NTLA $1.6B	–	–	–	–
155	155 OmniAb OABI $667M	–	–	–	–
156	OBX 156 Obsidian Therapeutics OBX $727M	–	–	–	–
157	157 DELISTED Omega Therapeutics, Inc. Common Stock OMGA	–	–	–	–
158	158 DELISTED Singular Genomics Systems, Inc. Common Stock OMIC	–	–	–	–
159	159 DELISTED Orgenesis Inc. Common Stock ORGS	–	–	–	–
160	ORTX 160 DELISTED Orchard Therapeutics plc American Depositary Shares ORTX	–	–	–	–
161	161 Passage Bio PASG $11.3M	–	–	–	–
162	162 PepGen PEPG $180M	–	–	–	–
163	163 PharmaCyte Biotech PMCB $3.65M	–	–	–	–
164	164 Prime Medicine PRME $629M	–	–	–	–
165	165 ProKidney PROK $278M	–	–	–	–
166	166 Personalis PSNL $1.67B	–	–	–	–
167	167 DELISTED Poseida Therapeutics, Inc. Common Stock PSTX	–	–	–	–
168	168 Quantum-Si Incorporated QSI $245M	–	–	–	–
169	RCOR 169 DELISTED Renovacor, Inc. RCOR	–	–	–	–
170	170 Atrium Therapeutics RNA $131M	–	–	–	–
171	171 Cartesian Therapeutics RNAC $190M	–	–	–	–
172	RUBY 172 DELISTED Rubius Therapeutics, Inc RUBY	–	–	–	–
173	173 Sana Biotechnology SANA $680M	–	–	–	–
174	SCPS 174 DELISTED Scopus BioPharma Inc. Common Stock SCPS	–	–	–	–
175	SCTX 175 Scribe Therapeutics Inc SCTX $380M	–	–	–	–